The Ocugen R&D Center is expected to have a positive economic impact in the region and provide substantial employment opportunities in the coming years
Posted Date – Thu, 18 May 23 at 06:19pm
Hyderabad: US-based biotech major Ocugen Inc. plans to establish a research and development center in Telangana that will focus on developing cutting-edge modified gene therapies and regenerative cell therapies for unmet medical needs, in addition to vaccines that support public health.
The announcement was made following a meeting between IT and Industry Minister KT Rama Rao and Dr. Shankar Musunuri, Ocugen Chairman, CEO and Co-Founder; Dr. Arun Upadhyay, Ocugen Chief Scientific Officer and Head of Research, Development and Medical; Dr. Ajay Potluri of the India Project.
Telangana Life Sciences Principal Secretary (Industry and Commerce) Jayesh Ranjan and Chief Executive Officer Shakthi M. Nagappan were also present.
“We look forward to expanding our presence in India and beginning to transform Ocugen into a truly global organization as we pursue new approaches to medicine – being bold and thinking differently about patients is at the center of everything we do,” said Dr. Musunuri explain.
“I am delighted to welcome Ocugen to Hyderabad. It is a testament to the state’s vibrant biotech industry and strong academic base, attracting local and international players to set up R&D centers. As we become a $250 billion eco- As part of the system’s 2030 vision, we have identified complex manufacturing and advanced therapeutics as key pillars of growth and I believe this investment is strategically focused on growth and I believe this investment focused on cell and gene therapy in nature Driving the development of the emerging field of life sciences,” said Minister Rama Rao.
The center is expected to have a positive economic impact in the region and provide substantial employment opportunities in the coming years.
Ocugen, Inc., headquartered in Pennsylvania, USA, is a biotechnology company focused on discovering, developing and commercializing new therapeutic options to improve health and bring hope to patients around the world through bold innovations. Ocugen’s novel R&D pipeline includes three unique platform technologies focused on ophthalmology, orthopedics and infectious disease.
Unlike traditional gene therapies, the company’s breakthrough modified gene therapy platform has the potential to treat multiple retinal diseases caused by multiple gene mutations with a single product. Currently, Ocugen has three modified gene therapy programs, OCU400 (for retinitis pigmentosa and Leber congenital amaurosis), OCU410 (for dry AMD) and OCU410ST (for ABCA4-related retinopathy). According to an official statement, Ocugen is the first company to bring this modifying gene therapy concept into the clinic globally.
glad to welcome @Ocugen to the vibrant Hyderabad biotech ecosystem as they are setting up an R&D center focused on modifying gene therapies and regenerative cell therapies, which is one of our key areas of focus as we look to triple life sciences … pic.twitter.com/HRzH6Bib1b
— KTR (@KTRBRS) May 18, 2023
